Explore how clinicians subtype depression using severity, stressors, suicidality, sleep, and anxiety patterns to sharpen diagnosis, guide treatment, and build trust.
Clinicians weigh ketamine vs FDA-approved esketamine for TRD, with evolving guidance on dosing, safety monitoring, and long-term maintenance decisions.
Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.